Rob Michael

“Avi delivered another excellent quarter, with results once again exceeding our expectations.”

“Like, I think what you're seeing is a continuation of the strategy where we've talked about a quick return to growth. We exceed our peak sales last year, just two years after the U.S. Humira LOE, with, I'd say, like four really strong growth drivers for the company.”

“AbbVie is off to an excellent start to the year, with first quarter results exceeding our expectations across our diverse portfolio. We are delivering top-tier growth and continue to strengthen our long-term outlook with pipeline advancements and strategic transactions.”

“Our fourth quarter performance closes out another excellent year for AbbVie, and I am very pleased with the significant progress we made in 2025.”

“AbbVie is off to an excellent start to the year with first quarter results exceeding expectations across several of our therapeutic areas. We also continued to advance our promising internal pipeline and add external opportunities to further strengthen our business and long-term outlook.”